- A gross income of $250,000 or more per annum in each of the previous two financial years; or
- Net assets of at least $2.5 million; and
- A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)
From the garage to a COVID-19 vaccine lab
When local synthetic antibiotics developer Recce Pharmaceuticals announced they had entered into an antiviral Sars-CoV-2...
Prescient Therapeutics is developing novel personalised therapies against a range of cancers – Small Caps
Prescient Therapeutics (ASX: PTX) Chief Executive Officer Steven Yatomi-Clarke joins Small Caps to discuss the...
Prescient Therapeutics: Next Gen CAR-T Platform a Potential Game Changer – Independent Investment Research
PTX has acquired the exclusive global licence to a universal immune receptor (UIR) platform from...
PTX Target Price Revision: Target Upped to A$0.20 – H.C Wainwright & Co
We maintain our Buy rating and are increasing our price target to A$0.20 from A$0.16...
PTX Target Price Revision – H.C Wainwright & Co
We maintain our Buy rating and are increasing our price target to A$0.16from A$0.09. The...